Results
The search strategy identified 14 total studies, of which 6 (n¼733 total patients) met the inclusion criteria. Three studies were conducted in an emergency setting, whereas the other 3 were performed in an inpatient psychiatric or other medical setting. Three studies compared droperidol with haloperidol, one study compared droperidol with olanzapine, one study compared droperidol with midazolam, and one study compared droperidol with placebo.
Overall, droperidol was associated with an increased likelihood of tranquilization, defined as a score less than 2 (asleep or settled) on a previously validated sedation scale, 1 within 30 minutes compared with placebo and no difference compared with haloperidol, olanzapine, or midazolam (Table) . Compared with haloperidol, droperidol was associated with a decreased risk of needing additional medication after 60 minutes (2 randomized controlled trials; n¼255; risk ratio¼0.37; 95% confidence interval 0.16 to 0.90). There was no difference in the need for additional medication at 60 minutes when droperidol was compared with midazolam or olanzapine. Adverse events rates were very low with droperidol, with no significant difference in the risk of cardiac dysrhythmias or airway complications noted in any of the trials. 
STUDY SELECTION
This systematic review included all randomized controlled trials that compared droperidol with any other treatment for acute psychotic illnesses (eg, schizophrenia, schizoaffective disorder, mixed affective disorders, acute mania, brief psychotic episodes). Studies in which the majority of participants were thought to have a form of mental illness were included. Quasirandomized studies (eg, studies performing drug allocation by day of week) were excluded. Studies in which greater than 50% of participants were lost to followup, in which participants had nonpsychiatric diagnoses (eg, alcohol intoxication), or in which treatment for the illness was not specified were also excluded.
Commentary
Mental health-related visits are a common emergency department (ED) presentation, with more than 5 million visits occurring per year. This review demonstrated that droperidol is a rapid and effective agent for the treatment of acute psychosis-induced agitation. However, it is important to consider several limitations with respect to this study. Only half of the studies were conducted in an ED. No studies assessed patients managed in the out-of-hospital environment, which is a common route for these patients to arrive at the hospital. Additionally, there was significant variation between studies, with most outcomes assessed by only one study. As a result, although data were available on 733 patients, most outcome assessments consisted of approximately 200 patients. This review did not include a recent randomized controlled trial demonstrating similar efficacy between olanzapine and droperidol with improved sedation noted in a third group who received droperidol with midazolam. 8 Therefore, it is possible that combined therapy is preferable to monotherapy; however, the aggregate risk of complication from combination therapy is unknown. Finally, providers should be aware of the black box warning for droperidol in the United States, which may limit the ability to use this medication in some EDs. 9 However, the current review, as well as a large observational trial of more than 1,000 patients, suggests that droperidol is safe, with low rates of QT prolongation and no cases of torsades de pointes identified in the cohorts. 10, 11 Further trials are needed to assess the safety and efficacy of droperidol among larger patient populations and in comparison with newer intranasal and inhaled antipsychotics. Additionally, studies should further assess the efficacy of combination therapy versus monotherapy for the management of acute psychosis.
Overall, this review suggests that droperidol is relatively safe and effective for the treatment of acute agitation in the ED setting. 
